Combination of Long-Acting Beta-Sympathomimetic and Anticholinergic for Respiratory Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for respiratory diseases like COPD and asthma using β-mimetics and anticholinergics often result in undesirable side-effects and inadequate long-term relief, necessitating frequent rescue medications.
Innovation Solution
A combination of a long-acting β-sympathomimetic and a long-acting anticholinergic, administered via inhalation, which reduces side-effects and provides a superadditive bronchospasmolytic effect, allowing for once-daily therapy with reduced need for short-acting rescue medications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If β-mimetics are used for bronchodilation, then bronchospasmolytic effect is improved, but side-effects on heart and central nervous system worsen
Solution Approach 1:
The patent combines two different mechanisms of action (β2-adrenergic receptor stimulation and muscarinic receptor antagonism) into a single therapeutic regimen. This combination allows achieving enhanced bronchodilation through multiple pathways while using lower doses of each individual agent, thereby reducing the side-effects associated with high-dose monotherapy.
2Object-affected harmful factors
If inhaled anticholinergics are used to reduce systemic side-effects, then therapeutic index is improved, but duration of action is insufficient
Solution Approach 1:
The patent combines short-acting inhaled anticholinergics with long-acting inhaled β2-mimetics to create a regimen that maintains both safety profile and extended duration of action. The long-acting β2-mimetic component provides sustained bronchodilation throughout the day, compensating for the shorter duration of the inhaled anticholinergic while maintaining low systemic exposure.
3Ease of operation
If frequent rescue medications are used to maintain control, then symptom relief is improved, but treatment complexity and patient burden worsen
Solution Approach 1:
The patent employs long-acting inhaled β2-mimetics that provide sustained bronchodilation over 12-24 hours, creating continuous therapeutic coverage. This reduces or eliminates the need for frequent rescue medications, simplifying the treatment regimen to once or twice daily administration while maintaining continuous symptom control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination significantly enhances bronchodilatory effects, offering rapid and prolonged relief from bronchospasm, reducing side-effects and the frequency of rescue medication use for COPD and asthma patients.
Implementation Method 1
the stimulation of β2-adrenergic receptors stimulates adenylate cyclase resulting in an increased level of the second messenger cAMP that in turn leads decreased intracellular calcium concentration and consequently smooth muscle relaxation
Implementation Method 2
This action results from their ability to inhibit the action of the neurotransmitter acetylcholine by blocking its binding to muscarinic cholinergic receptors
Data Source
AI summary
The present invention describes a combination of an anticholinergic, such as R,R-glycopyrrolate, and a β mimetic, such as tormoterol, for the treatment of respiratory diseases including airway inflammation or obstruction such as chronic obstructive pulmonary disease (COPD) and asthma.